CBD Reviews

Cbdca auc 2

Purpose: In recognition of the variety of available chemotherapeutic modulating agents and their potential to enhance the efficacy of platinum-based therapy, we embarked upon a phase I study to investigate the feasibility of combining fixed doses of carboplatinum (CBDCA) and etoposide (VP-16) with 24-h concurrent infusions of dipyridamole (DP), prochlorperazine (PCZ) and cyclosporine A (CSA Study protocol for an open-label, single-arm, multicentre phase Introduction Carboplatin (CBDCA) administered at a dosage of 4 mg/mL/min or more area under the blood concentration-time curve (AUC) is considered to be ranked as the highest chemotherapy-induced nausea and vomiting (CINV) risk of the moderately emetogenic chemotherapy agents. The complete response (CR) rate for preventing overall CINV, defined as no emetic episodes and no use of rescue NCCTG Status Report for Study N057E - April 2009 A Phase II Trial NCCTG Status Report for Study N057E - April 2009 NOVEL NCCTG NOVEL Committee N057E - Page 1 of 2 A Phase II Trial of Carboplatin (CBDCA) and ABI-007 (ABX) in Patients with A Phase I Study of Gemcitabine and Carboplatin in Patients with

Methods and analysis This trial is an open-label, single-arm, multicentre phase II trial. Patients who receive CBDCA (AUC ≥4)-based therapy and have never 

Preclinical and clinical evaluation of four gemcitabine plus Background: To explore the activity and tolerability of gemcitabine (GEM) and carboplatin (CBDCA) in non-small-cell lung cancer (NSCLC) we tested four administration sequences on H460 NSCLC cells, and at the same time performed a randomized phase II trial using analogous schedules. A phase I/II study of gemcitabine (GEM) and carboplatin (CBDCA 7333 Background: The purpose of this study was to determine maximum tolerated dose (MTD) of a combination of GEM plus CBDCA administration on a biweekly schedule for inoperable NSCLC, and to assess the efficacy and safety at that recommended dose (RD). Methods: Patients with inoperable stage IIIB and IV NSCLC included in this study were treated with CBDCA followed by GEM. CBDCA was given

METHODS: The patients received chemotherapy with carboplatin (CBDCA) with an area under the curve (AUC) of 5, and docetaxel (DTX) at 60 mg/m 2 tri-weekly for three cycles after surgery. The primary endpoint of this study was compliance, while the secondary endpoints were the adverse events (AE) and recurrence-free survival (RFS).

Phase I/II Study of Paclitaxel+Carboplatin for Refractory or Recurrent Non-small Cell Lung Cancer AKIHIKO GEMMA 1 , MASAHIRO SEIKE 1 , SEIJI KOSAIHIRA 1 , YUJI MINEGISHI 1 , NCCTG Status Report for Study N057E - September 2007 A Phase II - CBDCA AUC 2 IV over 30 minutes fol-lowing ABI-007 1, 8, 15 Every 28 days up to 8 cycles Grouping factors: Prior chemotherapy for metastatic disease: Yes vs No. A phase I study of carboplatin and etoposide administered in Purpose: In recognition of the variety of available chemotherapeutic modulating agents and their potential to enhance the efficacy of platinum-based therapy, we embarked upon a phase I study to investigate the feasibility of combining fixed doses of carboplatinum (CBDCA) and etoposide (VP-16) with 24-h concurrent infusions of dipyridamole (DP), prochlorperazine (PCZ) and cyclosporine A (CSA

CDDP/GEM, 非小細胞肺がん, CDDP 80 mg/m2(d1), CBDCA 併用レジメンは中等度または高度リスクに分類され,5-HT3 受容体拮抗薬,デキサメタゾンを中心に,必要時はアプレピタントを併用し,悪心・嘔吐対策を行う。 CBDCA AUC 5-6(d1):q3w.

Treatment consisted of a 1-hour i.v. infusion of 50 mg/m2 of PTX followed by a half-hour infusion of CBDCA AUC 2 administered weekly concurrently with